Samagya Banskota

About

Samagya Banskota, PhD, is an Assistant Professor in Biomedical Engineering at Boston University College of Engineering. She holds a PhD in Biomedical Engineering from Duke University and completed a postdoctoral fellowship in Chemistry and Chemical Biology at the Broad Institute of Harvard and MIT. Her research interests encompass drug delivery, biomolecular engineering, biomaterials design, genome editing, synthetic biology, functional genomics, and protein engineering. Her lab focuses on developing precision genome editing technologies aimed at treating genetic diseases by making targeted DNA modifications. A key aspect of her work involves addressing delivery challenges for therapeutics through the design of genetically-encoded and stimuli-responsive delivery systems, integrating synthetic biology and protein engineering. Additionally, her research explores the biological functions of transposable elements within the human genome, developing genome and epigenome editing technologies to serve as molecular recorders for studying their roles in diseases. Recognized as a Hartwell Investigator, she has been honored as one of MIT Technology Review's 35 Innovators Under 35 and received the Pratt-Gardner Graduate Fellowship.

Research topics

• Biology
• Biophysics
• Chemistry
• Materials science
• Internal medicine
• Nanotechnology
• Pharmacology
• Medicine
• Computational biology
• Combinatorial chemistry

Selected publications

• Delivery of genome editors with engineered virus-like particles

  Methods in enzymology on CD-ROM/Methods in enzymology · 2025-01-01 · 4 citations

  reviewSenior authorCorresponding
  PublisherDOI

• Pyruvate dehydrogenase kinase expression profile is a biomarker for cancer sensitivity to dichloroacetate-mediated growth inhibition

  bioRxiv (Cold Spring Harbor Laboratory) · 2023-09-22 · 3 citations

  preprintOpen access

  Abstract Background Cancer cells favour glycolysis and lactate production over mitochondrial metabolism despite the presence of oxygen (the Warburg effect). Increased pyruvate dehydrogenase kinase (PDK) activity contributes to this glycolytic phenotype. Dichloroacetate (DCA) is a PDK inhibitor with anti-cancer potential that inhibits all four isoforms of PDK but with differing potencies, thus expression of different isoforms may determine sensitivity to DCA. Methods The association of sensitivit…

  PublisherOA PDFDOI

• Dataset for: One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer

  Figshare · 2017-01-01 · 1 citations

  datasetOpen access

  Data from manuscript, titled "One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer", published in Nature Biomedical Engineering. <br>For other inquiries, please contact Ashutosh Chilkoti (chilkoti@duke.edu)

  PublisherDOI

• Development of Genetically Encoded Zwitterionic Polypeptides for Drug Delivery

  2019-01-01

  dissertation1st authorCorresponding
  Publisher

Frequent coauthors

• David R. Liu

  Howard Hughes Medical Institute

  40 shared

• Aditya Raguram

  Whitehead Institute for Biomedical Research

  31 shared

• Jessie R. Davis

  University College Dublin

  29 shared

• Peyton B. Randolph

  Howard Hughes Medical Institute

  27 shared

• Gregory A. Newby

  Howard Hughes Medical Institute

  21 shared

• Ashutosh Chilkoti

  Duke University

  19 shared

• Meirui An

  Broad Institute

  19 shared

• Xinghai Li

  Duke University

  17 shared

Education

• Ph.D., Materials Science and Engineering

  Boston University

  2015

• M.S., Materials Science and Engineering

  University of California, Santa Barbara

  2010

• B.S., Materials Science and Engineering

  University of California, Santa Barbara

  2009

Awards & honors

• MIT Technological Review 35 Innovators Under 35
• Pratt-Gardner Graduate Fellowship

Similar researchers at Boston University

• David Boash-156
• Thomas Bifanoh-37